April 27, 2021 -- Avantor plans to increase its manufacturing capability of single-use technologies for biologics and vaccines.
The company will increase its capacity in the U.S. and Europe by 30% and double its cleanroom space to support demand for monoclonal antibodies, cell and gene therapies for oncology, and vaccines, including those for COVID-19.
The firm has already expanded its facility in Morrisville, NC, and will expand another in Devens, MA, by mid-year. It also plans to open a second European single-use technology manufacturing site, in Hillegom, the Netherlands.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: